Uehling has been involved in the development and application of inhibitors of understudied kinases and in the discovery of potent disruptors of protein protein intereactions of oncogenic targets. A related interest is the use of small molecules to exploit synthetic lethalities and molecularly defined tumour vulnerabilities in the validation of early-stage cancer targets. Uehling also has a long-standing interest in the discovery and use of chemical probe compounds and their use in phenotypic screening. He seeks to apply his experience from the pharmaceutical industry to work with academic scientists to explore and advance the translational potential of early-stage research opportunities to identify clinical drug candidate molecules.

Uehling obtained his undergraduate degree in Chemistry at UC San Diego. After obtaining a PhD in synthetic organic chemistry at the University of California, Berkeley, he was a post-doctoral fellow at Yale and Harvard Universities. For approximately 19 years, Uehling worked at GlaxoSmithKline (GSK) or its legacy companies in cardiovascular, diabetes and oncology research.  While working at GSK, he was a member of the project team that identified the topoisomerase I inhibitor lurtotecan for colorectal cancer and the beta-3 agonist solabegron for type 2 diabestes. In addition, he served as medicinal chemistry team leader in the discovery of of the B-Raf inhibitor dabrafenib (Tafinlar™), which is currently marketed for the treatment of patients with unresectable melanoma with a BRAF V600 mutation as well as BRAF V600-positive advanced or metastatic non small-cell lung cancer in combination with the MEK inhibitor trametinib (Mekinist™).